[Experience with rovamycin and roxithromycin in patients with chronic bronchitis in the presence of posttuberculous changes].
Rovamycin and roxithromycin were comparatively studied for their effects in 25 patients with chronic bronchitis and posttuberculous changes in the lung. Ten patients received oral rovamycin, 3,000,000 IU, twice daily and 15 had oral roxithromycin, 150 mg, twice daily. The therapy averaged 9 days. Clinical cure was observed in 90% of cases on rovamycin and in 86.7% on roxithromycin. There were no adverse effects of these drugs. The findings suggest that due to their high therapeutical and bacteriological activities, both rovamycin and roxithromycin show their good clinical efficacy in the treatment of exacerbations of chronic bronchitis in patients with residual posttuberculous changes.
Sobeleva
L G
LG
Komlev
A D
AD
Korovina
O V
OV
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy* / Q000209:etiology*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015575:Roxithromycin / Q000627:therapeutic use*; D015572:Spiramycin / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications*
D000900:Anti-Bacterial Agents; D015575:Roxithromycin; D015572:Spiramycin